
The NF1 PNand HPP Patient Education Managers (PEMs) are an empathetic and trusted educational resource for NF1/HPP patients and families. They are responsible for engaging with the local NF1 and HPP patient community via 1:1 meetings; conducting unbranded and branded patient education at scale through programs; and (in close collaboration with Alexion’s Patient Advocacy team) partnering with local and regional NF1 and HPP advocacy groups to further raise awareness of NF1 and HPP burden, disease progression, and treatment.
In addition to these responsibilities, PEMs also refer patients and caregivers to Case Managers for case management support when starting on Alexion therapy and connect the NF1 and HPP community, as appropriate, to local advocacy networks and approved resources to best support patients and their families through the treatment journey.
The annual base pay (or hourly rate of compensation) for this position ranges from $135,332 to $202,998. Our positions offer eligibility for various incentives—an opportunity to receive short-term incentive bonuses, equity-based awards for salaried roles and commissions for sales roles. Benefits offered include qualified retirement programs, paid time off (i.e., vacation, holiday, and leaves), as well as health, dental, and vision coverage in accordance with the terms of the applicable plans.
16-Oct-2026
29-Oct-2026
Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.

Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community. We are driven by a mission to change what it means to live with a rare disease.
A leader in rare disease for more than three decades and today continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities.
As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally.
GL/NP/0116
GL/NP/0095
Community Guidelines: https://bit.ly/39x9gqy